- Home
- ALX vs NVCR Comparison
ALX vs NVCR Comparison
Compare ALX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- NVCR
- Stock Information
- Founded
- ALX 1928
- NVCR 2000
- Country
- ALX United States
- NVCR Switzerland
- Employees
- ALX N/A
- NVCR N/A
- Industry
- ALX Real Estate Investment Trusts
- NVCR Medical/Dental Instruments
- Sector
- ALX Real Estate
- NVCR Health Care
- Exchange
- ALX Nasdaq
- NVCR Nasdaq
- Market Cap
- ALX 1.2B
- NVCR 1.4B
- IPO Year
- ALX N/A
- NVCR 2015
- Fundamental
- Price
- ALX $244.39
- NVCR $12.15
- Analyst Decision
- ALX
- NVCR Buy
- Analyst Count
- ALX 0
- NVCR 7
- Target Price
- ALX N/A
- NVCR $28.79
- AVG Volume (30 Days)
- ALX 42.2K
- NVCR 1.3M
- Earning Date
- ALX 11-03-2025
- NVCR 10-29-2025
- Dividend Yield
- ALX 7.37%
- NVCR N/A
- EPS Growth
- ALX N/A
- NVCR N/A
- EPS
- ALX 7.28
- NVCR N/A
- Revenue
- ALX $218,089,000.00
- NVCR $630,160,000.00
- Revenue This Year
- ALX N/A
- NVCR $6.68
- Revenue Next Year
- ALX N/A
- NVCR $7.01
- P/E Ratio
- ALX $33.54
- NVCR N/A
- Revenue Growth
- ALX N/A
- NVCR 14.58
- 52 Week Low
- ALX $184.76
- NVCR $10.87
- 52 Week High
- ALX $260.84
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- ALX 64.45
- NVCR 46.57
- Support Level
- ALX $232.45
- NVCR $11.98
- Resistance Level
- ALX $238.24
- NVCR $12.83
- Average True Range (ATR)
- ALX 5.30
- NVCR 0.56
- MACD
- ALX 2.10
- NVCR 0.15
- Stochastic Oscillator
- ALX 85.67
- NVCR 25.49
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.